Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

D. Ilo · SciRah

Researcher profile · Semantic Scholar

D. Ilo

Share profile

D. Ilo — researcher profile on SciRah

h-index: 12
Works: 51
Citations: 476

Most-cited papers

Upadacitinib Therapy Reduces Ulcerative Colitis Symptoms as Early as Day 1 of Induction Treatment.
E. Loftus, J. Colombel, K. Takeuchi, Xiang Gao +13 more
2022Clinical Gastroenterology and Hepatology83 citations Open access
Semantic Scholar
Efficacy and Safety of Advanced Therapies for Moderately to Severely Active Ulcerative Colitis at Induction and Maintenance: An Indirect Treatment Comparison Using Bayesian Network Meta-analysis
R. Panaccione, E. B. Collins, G. Melmed, S. Vermeire +8 more
2023Crohn's & Colitis 36050 citations Open access
Semantic Scholar
Microvascular dysfunction and efficacy of PDE5 inhibitors in BPH–LUTS
S. Cellek, N. Cameron, M. Cotter, C. Fry +1 more
2014Nature reviews. Urology41 citations
Semantic Scholar
Efficacy and safety of upadacitinib maintenance therapy for moderately to severely active ulcerative colitis in patients responding to 8 week induction therapy (U-ACHIEVE Maintenance): overall results from the randomised, placebo-controlled, double-blind, phase 3 maintenance study.
S. Vermeire, S. Danese, Wen Zhou, D. Ilo +13 more
2023The Lancet Gastroenterology and Hepatology36 citations
Semantic Scholar
Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3)
A. Blauvelt, K. Papp, C. Griffiths, L. Puig +6 more
2017American Journal of Clinical Dermatology35 citations Open access
Semantic Scholar
Effect of tadalafil on male lower urinary tract symptoms: an integrated analysis of storage and voiding international prostate symptom subscores from four randomised controlled trials.
C. Chapple, C. Roehrborn, K. McVary, D. Ilo +2 more
2015European Urology34 citations
Semantic Scholar
Effects of tadalafil treatment after bilateral nerve-sparing radical prostatectomy: quality of life, psychosocial outcomes, and treatment satisfaction results from a randomized, placebo-controlled phase IV study
H. Patel, D. Ilo, N. Shah, B. Cuzin +7 more
2015BMC Urology28 citations Open access
Semantic Scholar
Efficacy and safety of upadacitinib for 16‐week extended induction and 52‐week maintenance therapy in patients with moderately to severely active ulcerative colitis
R. Panaccione, S. Danese, Wen Zhou, J. Klaff +14 more
2023Alimentary Pharmacology and Therapeutics25 citations Open access
Semantic Scholar
Upadacitinib Induction and Maintenance Therapy Improves Abdominal Pain, Bowel Urgency, and Fatigue in Patients With Ulcerative Colitis: A Post Hoc Analysis of Phase 3 Data
S. Danese, Jacinda Tran, G. D'Haens, David T. Rubin +6 more
2023Inflammatory Bowel Diseases22 citations Open access
Semantic Scholar
Correlation of mucosal healing endpoints with long-term clinical and patient-reported outcomes in ulcerative colitis
G. Parkes, R. Ungaro, S. Danese, M. Abreu +7 more
2023Journal of gastroenterology21 citations Open access
Semantic Scholar
OP33 Effect of upadacitinib (UPA) treatment on extraintestinal manifestations (EIMs) in patients with moderate-to-severe Ulcerative Colitis (UC): Results from the UPA Phase 3 programme
J. Colombel, Q. Cao, S. Ghosh, W. Reinisch +5 more
2022Journal of Crohn's & Colitis20 citations
Semantic Scholar
Induction and Maintenance Treatment With Upadacitinib Improves Health-Related Quality of Life in Patients With Moderately to Severely Active Ulcerative Colitis: Phase 3 Study Results
J. Panés, E. Loftus, P. Higgins, J. Lindsay +7 more
2023Inflammatory Bowel Diseases15 citations Open access
Semantic Scholar
DOP41 Efficacy and safety of extended induction treatment with upadacitinib 45 mg once daily followed by maintenance upadacitinib 15 or 30 mg once daily in patients with moderately to severely active Ulcerative Colitis
S. Vermeire, S. Danese, W. Zhou, J. Klaff +6 more
2022Journal of Crohn's & Colitis11 citations Open access
Semantic Scholar
P573 The safety profile of upadacitinib maintenance therapy in ulcerative colitis in the Phase 3 U-ACHIEVE study is consistent with that in approved indications
J. Colombel, R. Panaccione, H. Nakase, G. Burmester +7 more
2022Journal of Crohn's & Colitis8 citations
Semantic Scholar
Ulcerative Colitis-Symptom Questionnaire: Valid for Use in Adults with Moderately to Severely Active Ulcerative Colitis
J. Panés, A. Otley, Y. Sanchez Gonzalez, K. Fitzgerald +4 more
2023Digestive Diseases and Sciences7 citations Open access
Semantic Scholar
DOP39 Effect of baseline disease characteristics on clinical outcomes in moderate-to-severe Ulcerative Colitis treated with upadacitinib: Results from a Phase 3 trials programme
P. Higgins, J. Colombel, M. Reguiero, G. Parkes +5 more
2022Journal of Crohn's & Colitis6 citations
Semantic Scholar
OP34 Efficacy and safety of advanced induction and maintenance therapies in patients with moderately to severely active Ulcerative Colitis: An indirect treatment comparison using Bayesian network meta-analysis
R. Panaccione, E. B. Collins, G. Melmed, S. Vermeire +7 more
2022Journal of Crohn's & Colitis5 citations
Semantic Scholar
S856 Efficacy of Upadacitinib Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis by Biologic Inadequate Responder Status: Results From Two Randomized Phase 3 Studies
S. Vermeire, S. Tanida, Ren-Wei Hu, R. Panaccione +7 more
2021American Journal of Gastroenterology5 citations
Semantic Scholar
P370 Maintenance of health-related quality of life improvements with upadacitinib treatment among patients with moderately to severely active ulcerative colitis: results from, 52-week phase, 3 study U ACHIEVE maintenance
J. Panés, E. Loftus, P. Higgins, J. Lindsay +7 more
2022Journal of Crohn's & Colitis4 citations Open access
Semantic Scholar
P658 Comparative Efficacy and Safety of Upadacitinib Versus Tofacitinib as Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: A Matching-Adjusted Indirect Comparison
W. Reinisch, J. Tran, K. Patel, N. Borruel +6 more
2023Journal of Crohn's & Colitis3 citations
Semantic Scholar
P521 Correlation of histological assessment of mucosal healing with long-term clinical and patient-reported outcomes in patients with moderately to severely active ulcerative colitis treated with upadacitinib: results from the Phase 3 U-ACHIEVE maintenance trial
G. Parkes, R. Ungaro, S. Danese, M. Abreu +7 more
2022Journal of Crohn's & Colitis3 citations
Semantic Scholar
S805 Efficacy of Upadacitinib Dose Escalation in a Phase 3 Long-Term Extension Ulcerative Colitis Study
R. Panaccione, Millie D. Long, Z. Ran, R. Atreya +5 more
2022American Journal of Gastroenterology3 citations
Semantic Scholar
Correction to: Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3)
A. Blauvelt, K. Papp, C. Griffiths, L. Puig +6 more
2018American Journal of Clinical Dermatology3 citations Open access
Semantic Scholar
P546 Comparative efficacy and safety of upadacitinib versus ustekinumab as induction therapy in patients with moderately to severely active ulcerative colitis: A matching-adjusted indirect comparison
W. Reinisch, R. Panaccione, M. Duijvestein, D. Santos +6 more
2023Journal of Crohn's & Colitis2 citations Open access
Semantic Scholar
S712 Benefits of High versus Low Dose Upadacitinib as Maintenance Treatment in Ulcerative Colitis Patients Who Were Responders to 8-week Induction with Upadacitinib: Results From the U-ACHIEVE Phase 3 Maintenance Trial
G. Parkes, P. Juillerat, K. Gecse, Xuan Yao +5 more
2022Gastroenterology & hepatology2 citations
Semantic Scholar
MP48-13 EFFECTS OF TADALAFIL TREATMENT POST BILATERAL NERVE-SPARING RADICAL PROSTATECTOMY (NSRP): QUALITY OF LIFE (QOL), PSYCHOSOCIAL OUTCOMES AND TREATMENT SATISFACTION
H. Patel, N. Shah, Jonas Lundmark, J. Jones +4 more
20142 citations
Semantic Scholar
P52 Benefits of high versus low dose upadacitinib as maintenance treatment in ulcerative colitis
B. Feagan, G. Parkes, P. Juillerat, K. Gecse +6 more
2023Poster presentations1 citations
Semantic Scholar
Tu1454: THE SAFETY PROFILE OF UPADACITINIB MAINTENANCE THERAPY IN ULCERATIVE COLITIS IN THE PHASE 3 U-ACHIEVE STUDY IS CONSISTENT WITH THAT IN APPROVED INDICATIONS
J. Colombel, R. Panaccione, H. Nakase, G. Burmester +7 more
2022Gastroenterology1 citations
Semantic Scholar
Tu1449: EFFICACY AND SAFETY OF ADVANCED INDUCTION AND MAINTENANCE THERAPIES IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: AN INDIRECT TREATMENT COMPARISON USING BAYESIAN NETWORK META-ANALYSIS
R. Panaccione, E. B. Collins, G. Melmed, S. Vermeire +7 more
2022Gastroenterology1 citations
Semantic Scholar
Tu1455: EFFECT OF UPADACITINIB (UPA) TREATMENT ON EXTRAINTESTINAL MANIFESTATIONS (EIMS) IN PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS (UC): RESULTS FROM THE UPA PHASE 3 PROGRAMME
J. Colombel, Qian Cao, Subrata Ghosh, W. Reinisch +5 more
2022Gastroenterology1 citations
Semantic Scholar
Tu1471: IMPACT OF CORTICOSTEROID USAGE ON EFFICACY AND SAFETY OUTCOMES IN PATIENTS RECEIVING UPADACITINIB FOR ULCERATIVE COLITIS
T. Raine, Y. Ishiguro, D. Rubin, T. Finney-Hayward +5 more
2022Gastroenterology1 citations
Semantic Scholar
S1028 Symptoms and Laboratory Values as Proxies for Endoscopic and Histologic Clinical Endpoints in Ulcerative Colitis: A Mediation Analysis Based on Upadacitinib Phase 3 Induction Trials
M. Dubinsky, Min Yang, M. Fillbrunn, S. Danese +7 more
2022American Journal of Gastroenterology1 citations
Semantic Scholar
S740 Efficacy and Safety of Upadacitinib Maintenance Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Final Results From the Phase 3 U-ACHIEVE Maintenance Study
S. Vermeire, S. Danese, Xuan Yao, D. Ilo +7 more
2022American Journal of Gastroenterology1 citations
Semantic Scholar
S773 Rapidity of Symptom Control with Upadacitinib Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Results From Two Randomized Phase 3 Studies
E. Loftus, K. Takeuchi, Xiang Gao, R. Panaccione +6 more
2021American Journal of Gastroenterology1 citations
Semantic Scholar
Patient characteristics and treatment patterns for patients with benign prostatic hyperplasia, erectile dysfunction or co‐occurring benign prostatic hyperplasia and erectile dysfunction in general practices in the UK: a retrospective observational study
D. Ilo, M. Raluy-Callado, P. Graham-Clarke, R. Sadasivan +5 more
2015International journal of clinical practice1 citations
Semantic Scholar
P120 Upadacitinib for moderate-to-severe ulcerative colitis: interim results from U-ACTIVATE phase III open-label extension
R. Panaccione, P. Higgins, Gary R. Lichtenstein, H. Nakase +10 more
2024Poster Presentations0 citations
Semantic Scholar
P51 Benefit-risk of upadacitinib in patients with moderately to severe ulcerative colitis (UC)
R. Panaccione, I. Blumenstein, P. Irving, C. Hedin +6 more
2023Poster presentations0 citations
Semantic Scholar
THE STUDY OF THE LIVER
B. Feagan, Gareth C. Parkes, P. Juillerat, K. Gecse +218 more
20230 citations
Semantic Scholar
OP20 The effects of upadacitinib on ulcerative colitis symptom resolution and fatigue normalization in patients with moderately to severely active ulcerative colitis: Phase 3 U-ACHIEVE and U-ACCOMPLISH results
G. D'Haens, J. Tran, S. Danese, D. Rubin +7 more
2023Journal of Crohn's & Colitis0 citations Open access
Semantic Scholar
966: EFFICACY AND SAFETY OF EXTENDED INDUCTION TREATMENT WITH UPADACITINIB 45 MG ONCE DAILY FOLLOWED BY MAINTENANCE UPADACITINIB 15 OR 30 MG ONCE DAILY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
S. Vermeire, S. Danese, Wen Zhou, J. Klaff +6 more
2022Gastroenterology0 citations
Semantic Scholar
Tu1459: CORRELATION OF HISTOLOGICAL ASSESSMENT OF MUCOSAL HEALING WITH LONG-TERM CLINICAL AND PATIENT-REPORTED OUTCOMES IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH UPADACITINIB: RESULTS FROM PHASE 3 U-ACHIEVE MAINTENANCE TRIAL
G. Parkes, R. Ungaro, S. Danese, M. Abreu +7 more
2022Gastroenterology0 citations
Semantic Scholar
S733 Impact of Inflammatory Burden on Efficacy of Upadacitinib Maintenance Therapy in Ulcerative Colitis: Results From the Phase 3 U-ACHIEVE Study
B. Feagan, J. Colombel, J. Torres, T. Fujii +5 more
2022American Journal of Gastroenterology0 citations
Semantic Scholar
Tu1448: EFFECT OF BASELINE DISEASE CHARACTERISTICS ON CLINICAL OUTCOMES IN MODERATE-TO-SEVERE ULCERATIVE COLITIS TREATED WITH UPADACITINIB: RESULTS FROM A PHASE 3 TRIALS PROGRAMME
P. Higgins, J. Colombel, M. Regueiro, G. Parkes +5 more
2022Gastroenterology0 citations
Semantic Scholar
S777 Benefit–Risk Assessment of Upadacitinib Treatment in Patients With Moderately to Severely Active Ulcerative Colitis
R. Panaccione, I. Blumenstein, P. Irving, D. Ilo +4 more
2022American Journal of Gastroenterology0 citations
Semantic Scholar
967: UPADACITINIB THERAPY REDUCES ULCERATIVE COLITIS SYMPTOMS AS EARLY AS DAY 1
S. Vermeire, J. Colombel, K. Takeuchi, Xiang Gao +11 more
2022Gastroenterology0 citations
Semantic Scholar
S739 Matching-Adjusted Indirect Comparison of Upadacitinib versus Vedolizumab as Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis
W. Reinisch, S. Vermeire, C. Hedin, J. Panés +8 more
2022American Journal of Gastroenterology0 citations
Semantic Scholar
S854 Upadacitinib Is Effective at Inducing Clinical Remission and Response in Ulcerative Colitis Patients Regardless of Baseline Corticosteroid Use: Results From Two Phase 3 Studies
D. Rubin, T. Raine, T. Finney-Hayward, E. Loftus +6 more
2021American Journal of Gastroenterology0 citations
Semantic Scholar
Tadalafil nach nerverhaltender radikaler Prostatektomie
H. Patel, D. Ilo, N. Shah
2015Urologie Scan0 citations
Semantic Scholar
Patient Characteristics and Medication Treatment Patterns Among Men With Erectile Dysfunction (Ed), Lower Urinary Tract Symptoms Secondary To Benign Prostatic Hyperplasia (Bph-Luts), Or Co-Occurring Ed and Bph-Luts In the Uk Primary Care Setting.
D. Ilo, M. Raluy-Callado, P. Graham-Clarke, R. Donaldson +4 more
2014Value in Health0 citations Open access
Semantic Scholar
POS-02.41: Urinary tract infections are uncommon after instalation of intravesical mitomycin C
S. Woźniak, N. Kuppurajan, C. Kouriefs, D. Ilo +1 more
20070 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

Wen Zhou×23
Invite
Wen Zhou — researcher profile on SciRah
R. Panaccione×22
Invite
R. Panaccione — researcher profile on SciRah
S. Danese×16
Invite
S. Danese — researcher profile on SciRah
S. Vermeire×12
Invite
S. Vermeire — researcher profile on SciRah

×11

Invite

Xuan Yao — researcher profile on SciRah

J. Colombel×10

Invite

J. Colombel — researcher profile on SciRah

Invite

P. Higgins — researcher profile on SciRah

Y. S. Gonzalez×9

Invite

Y. S. Gonzalez — researcher profile on SciRah

Invite

G. Levy — researcher profile on SciRah

Invite

X. Yao — researcher profile on SciRah

Y. Sanchez Gonzalez×7

Invite

Y. Sanchez Gonzalez — researcher profile on SciRah

Invite

W. Zhou — researcher profile on SciRah